Emibetuzumab

CAS No. 1365287-97-3

Emibetuzumab( —— )

Catalog No. M36695 CAS No. 1365287-97-3

Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 223 Get Quote
5MG 425 Get Quote
10MG 677 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Emibetuzumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer.
  • Description
    Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer.
  • In Vitro
    Emibetuzumab (LY2875358) (100 nmol/L; 6 days) inhibits HGF-stimulated proliferation of H596.Cell Proliferation Assay Cell Line:H596 cells (HGF-stimulated) Concentration:100 nmol/L Incubation Time:6 days Result:Suppressed cell proliferation.
  • In Vivo
    Emibetuzumab (LY2875358) (10 mg/kg; i.v.; once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice.Emibetuzumab (10 or 20 mg/kg; i.v.; single) downregulates levels of MET and pMET in the tumors of mice.Emibetuzumab (10 mg/kg; i.v.; once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models.Animal Model:Athymic nude mice (U87MG tumor xenograft model).Dosage:10 mg/kg Administration: Intravenous injection, once a week for 5 weeks.Result:Demonstrated a significant inhibition of tumor growth.Animal Model:Athymic nude mice (MKN45 xenograft tumor model).Dosage:10 or 20 mg/kg Administration:Intravenous injection, single.Result:Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days.Animal Model:Athymic nude mice (MET-amplified xenograft mouse tumor models).Dosage:10 mg/kg Administration:Intravenous injection, once a week for 3, 5 or 6 weeks. Result:Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    c-Met/HGFR
  • Recptor
    c-Met/HGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1365287-97-3
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Liu L, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1;20(23):6059-70. ?
molnova catalog
related products
  • BMS 777607

    BMS 777607 is a potent, selective, orally efficacious inhibitor of Met kinase with IC50 of 3.9 nM.

  • SAR125884 hydrochlor...

    SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile(IC50=4.2 nM).

  • AMG-208

    AMG-208 is a potent, small-molecule c-Met inhibitor with IC50 of 5.2 nM against wt MET kinase, also inhibits VEGFR2 with IC50 of 112 nM.